立体定向放射外科治疗放疗诱发脑膜瘤的多中心研究
中位影像随访48个月,9例(17%)进展,5年无进展生存率83%,治疗体积≥5 cm3预测进展。SRS对多数放疗诱发脑膜瘤可实现持久局部控制,安全性可接受。
要点
- SRS治疗放疗诱发WHO I级脑膜瘤5年无进展生存率83%。
- 治疗体积≥5 cm3与进展风险升高相关。
- SRS可作为手术条件不佳或术后再进展患者的可选方案。
核心结论
- SRS对多数放疗诱发脑膜瘤可实现持久局部控制,安全性可接受。
主要发现
- 中位影像随访48个月(范围4–195个月),9例(17%)在SRS后中位30个月(范围3–45个月)出现进展。
- SRS后5年无进展生存率为83%。
- 治疗体积≥5 cm3预测进展(HR 8.226,95%CI 1.028–65.857,p=0.047)。
- 7例(14%)在SRS后1至72个月出现新发神经症状、SRS相关并发症或T2信号改变。
临床怎么用
- 对于手术条件不佳或肿瘤切除后再次进展的放疗诱发WHO I级脑膜瘤患者,可考虑SRS治疗。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: Radiation-induced meningiomas (RIMs) are associated with aggressive clinical behavior. Stereotactic radiosurgery (SRS) is sometimes considered for selected RIMs. The authors investigated the effectiveness and safety of SRS for the management of RIMs. METHODS: From 12 institutions participating in the International Radiosurgery Research Foundation, the authors pooled patients who had prior cranial irradiation and were subsequently clinically diagnosed with WHO grade I meningiomas that were managed with SRS. RESULTS: Fifty-two patients underwent 60 SRS procedures for histologically confirmed or radiologically suspected WHO grade I RIMs. The median ages at initial cranial radiation therapy and SRS for RIM were 5.5 years and 39 years, respectively. The most common reasons for cranial radiation therapy were leukemia (21%) and medulloblastoma (17%). There were 39 multiple RIMs (35%), the mean target volume was 8.61 ± 7.80 cm3, and the median prescription dose was 14 Gy. The median imaging follow-up duration was 48 months (range 4-195 months). RIM progressed in 9 patients (17%) at a median duration of 30 months (range 3-45 months) after SRS. Progression-free survival at 5 years post-SRS was 83%. Treatment volume ≥ 5 cm3 predicted progression (HR 8.226, 95% CI 1.028-65.857, p = 0.047). Seven patients (14%) developed new neurological symptoms or experienced SRS-related complications or T2 signal change from 1 to 72 months after SRS. CONCLUSIONS: SRS is associated with durable local control of RIMs in the majority of patients and has an acceptable safety profile. SRS can be considered for patients and tumors that are deemed suboptimal, poor surgical candidates, and those whose tumor again progresses after removal.
引用
- Bunevicius A, Suleiman M, Patel S, et al. Stereotactic radiosurgery for treatment of radiation-induced meningiomas: a multiinstitutional study. J Neurosurg. 2021. PMID: 33385995. doi:10.3171/2020.7.JNS202064
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。